SCIAMPA M 12.5MG+500MG TABLET

SCIAMPA M 12.5MG+500MG TABLET

Home/Store/Medicines
Rs447
In stock
1
Save this product for later
Customer reviews
Reviews only from verified customers
No reviews yet. You can buy this product and be the first to leave a review.
Share this product with your friends
ShareSharePin it
SCIAMPA M 12.5MG+500MG TABLET
Home/Store/Medicines
Product Details
Brand: SCILIFE PHARMA
Units in Pack: 14
Generic: Metformin, Empagliflozin
Appearence / Physical Form: TABLET

SCIAMPA M 12.5mg + 500mg Tablet – Scilife Pharma | Dual-Action Diabetes Control (Empagliflozin + Metformin)

SCIAMPA M 12.5mg + 500mg Tablet by Scilife Pharma is a combination therapy designed for adults with Type 2 Diabetes Mellitus who require effective blood sugar control. This tablet combines:

  • Empagliflozin 12.5mg – an SGLT2 inhibitor that helps remove excess glucose through urine, supporting blood sugar reduction, weight management, and cardiovascular protection.
  • Metformin 500mg – a biguanide that decreases liver glucose production and improves insulin sensitivity, ensuring stable blood sugar levels throughout the day.

By targeting blood glucose through two complementary mechanisms, SCIAMPA M 12.5mg + 500mg provides superior glycemic control while improving heart, kidney, and metabolic health.


⭐ Key Benefits of SCIAMPA M (12.5mg + 500mg)

✔ Dual Mechanism for Comprehensive Blood Sugar Control

  • Empagliflozin removes excess glucose via urine.
  • Metformin lowers liver glucose output and enhances insulin function.
  • Together, they provide enhanced HbA1c reduction and balanced glucose management.

✔ Supports Weight Management

  • Helps reduce glucose-related calories
  • Promotes healthy weight loss
  • Improves overall metabolic efficiency

✔ Cardiovascular Protection

Empagliflozin reduces the risk of:

  • Heart failure hospitalization
  • Cardiovascular complications in diabetic patients

✔ Kidney Health Support

Slows the progression of diabetic nephropathy by reducing kidney strain and glucose load.

✔ Convenient Once-Daily Tablet

Reduces pill burden by combining two medications in one, improving adherence and simplifying diabetes management.


📌 Indications / Uses

Doctors prescribe SCIAMPA M 12.5mg + 500mg Tablet for:

  • Type 2 Diabetes Mellitus
  • Insufficient control with monotherapy (Metformin or Empagliflozin alone)
  • Overweight or obese diabetic patients
  • Cardiovascular risk in diabetic patients
  • Blood sugar management requiring combination therapy

Not recommended for:

  • Type 1 Diabetes
  • Diabetic ketoacidosis

📦 Product Details

  • Brand: Scilife Pharma
  • Generic: Empagliflozin + Metformin
  • Strength: 12.5mg + 500mg
  • Form: Tablet
  • Pack Size: 14 Tablets
  • Category: Anti-Diabetic, Combination Therapy

🕒 How to Use

  • Take one tablet once daily with meals, or as prescribed by your doctor.
  • Swallow whole with water; do not crush or chew.
  • Ensure adequate hydration while using Empagliflozin.
  • Follow your doctor’s dosage instructions strictly.

⚠️ Precautions & Possible Side Effects

Possible mild side effects include:

  • Increased urination
  • Gastrointestinal discomfort
  • Mild dehydration
  • Yeast infections (rare)

Seek immediate medical attention for:

  • Severe urinary tract symptoms
  • Signs of lactic acidosis (rare with Metformin)
  • Allergic reactions

🌐 Why Buy from Us?

  • 100% original Scilife Pharma product
  • Proper storage and handling
  • Affordable price in Pakistan
  • Fast, nationwide delivery
  • Trusted online pharmacy platform

⭐ Customer Reviews

⭐⭐⭐⭐⭐ “Dual-action tablet is very effective. Blood sugar is stable, and it’s easy to take once daily.” – Sana, Lahore
⭐⭐⭐⭐⭐ “Good combination medicine for diabetes. Works well and authentic product.” – Imran, Karachi

Show More
  • Search Products
  • My Account
  • Track Orders
  • Favorites
  • Shopping Bag
Display prices in:PKR
Skip to main content
Super Care
Menu
Home
Store
Delivery
FAQ's
Partners & Programs
Return Policy
About Us
Contact Us
My Account

SUPERCARE PHARMA © Supercare Pharmacy. All Rights Reserved (2025)

Terms & ConditionsCookie settingsReport abuse
Powered by Lightspeed